Abstract: Click HereStephanie E. Barrett, PhD., is a Principal Scientist at Merck & Co., Inc. She received her B. Sc. (Honors Chemistry) from McMaster University (Hamilton, Ontario, Canada) and her Ph.D. in Chemistry from the University of North Carolina at Chapel Hill. She joined Merck & Co., Inc. in 2009 in the Department of Medicinal Chemistry, where she led the development of bioerodible polymer-conjugate based siRNA delivery. Dr. Barrett then transitioned to formulation sciences and is now on the leadership team in the Department of Biopharmaceutics and Specialty Dosage Forms. Stephanie is one of Merck’s leading experts in polymer and bioconjugate chemistry for enabled delivery of small molecule and macromolecular drugs, having made influential contributions to the discovery of novel polymer conjugates for siRNA therapeutics, polymer excipients for oral dosage forms, and polymer-based long acting injectables. Throughout her time at Merck, she took on roles of increasing responsibility and is currently leading the team responsible for the design of Merck’s next generation of long acting implant products—with potential applications in HIV and other infectious diseases. She was recently named one of Business Insider’s 30 under 40 emerging leaders in biotech and pharmaceutical companies. Dr. Barrett holds 8 patents in the area of drug delivery, has authored 20 original publications in peer-reviewed journals, serves on the editorial advisory board of the Journal of DNA and RNA Research and the International Journal of Nanotechnology in Medicine & Engineering and is an active member of Merck’s Women in Science network.